The Emergence and Growth of Biotechnology
Show Less

The Emergence and Growth of Biotechnology

Experiences in Industrialised and Developing Countries

Rohini Acharya

This innovative book examines the development and evolution of biotechnology in industrialised and developing countries.
Buy Book in Print
Show Summary Details
You do not have access to this content

Chapter 8: Concluding Remarks

Rohini Acharya


Page 117 8—  Concluding Remarks The scientific development of biotechnology, followed by its technological commercialisation has followed very different patterns in different countries. The intention of  the book was to compare and contrast the development of biotechnology in different countries with different levels of scientific and technological capability. In doing  so, we first examined the development of the technology among a group of industrialised countries with similar levels of scientific and technological capabilities,  followed by the experiences of a group of technological followers. The experiences of all the countries are dependent on their scientific strengths, their economic and social environments and their technological and industrial structures.  However, there has been a tendency among countries, be they industrialised or developing, to follow patterns of development established in other countries where  biotechnology was introduced earlier. Thus, the spread of biotechnology in industrialised countries such as the United States, in the 1970s and 1980s, led to the  establishment of 'biotechnology programmes', or 'biotechnology directorates', in many countries to hasten the diffusion of the technology. Many industrialised and  developing countries established nationwide programmes for the development of biotechnology during the 1980s, which aimed to define national agendas and priorities  for biotechnology. This was followed by attempts to improve the commercialisation of biotechnology, following patterns established primarily in the United States. Thus, the small  biotechnology company became the key to commercialisation and venture capital the key to finance. Most European countries have active programmes to encourage  the development of small biotechnology companies which are often...

You are not authenticated to view the full text of this chapter or article.

Elgaronline requires a subscription or purchase to access the full text of books or journals. Please login through your library system or with your personal username and password on the homepage.

Non-subscribers can freely search the site, view abstracts/ extracts and download selected front matter and introductory chapters for personal use.

Your library may not have purchased all subject areas. If you are authenticated and think you should have access to this title, please contact your librarian.

Further information

or login to access all content.